Jan Štraub

1.5k total citations
39 papers, 332 citations indexed

About

Jan Štraub is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Jan Štraub has authored 39 papers receiving a total of 332 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Hematology, 25 papers in Oncology and 24 papers in Molecular Biology. Recurrent topics in Jan Štraub's work include Multiple Myeloma Research and Treatments (29 papers), Protein Degradation and Inhibitors (16 papers) and Cancer Treatment and Pharmacology (12 papers). Jan Štraub is often cited by papers focused on Multiple Myeloma Research and Treatments (29 papers), Protein Degradation and Inhibitors (16 papers) and Cancer Treatment and Pharmacology (12 papers). Jan Štraub collaborates with scholars based in Czechia, United States and Spain. Jan Štraub's co-authors include Ivan Špıčka, Hugh S. Vine, Michael J. Hallisey, Fernando F. Illescas, Steven K. Sussman, Rune R. Frants, H.P.M. Festen, S. G. M. Meuwissen, J. Défize and Roman Hájek and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Jan Štraub

35 papers receiving 315 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jan Štraub Czechia 10 163 133 104 96 91 39 332
Leanne McCulloch United States 8 261 1.6× 233 1.8× 202 1.9× 73 0.8× 25 0.3× 16 459
Yeu‐Chin Chen Taiwan 11 136 0.8× 54 0.4× 51 0.5× 34 0.4× 84 0.9× 55 313
Yasufumi Matsuda Japan 10 65 0.4× 93 0.7× 70 0.7× 60 0.6× 33 0.4× 27 259
Ming‐Chih Chang Taiwan 11 151 0.9× 97 0.7× 91 0.9× 71 0.7× 26 0.3× 31 373
Álvaro Hernández Vicente Spain 9 101 0.6× 149 1.1× 33 0.3× 43 0.4× 70 0.8× 18 414
Ajoy Dias United States 9 71 0.4× 41 0.3× 57 0.5× 36 0.4× 27 0.3× 27 216
M.C. Trzeciak France 12 318 2.0× 63 0.5× 21 0.2× 72 0.8× 54 0.6× 20 424
S. Luzi Fedeli Italy 6 176 1.1× 20 0.2× 123 1.2× 63 0.7× 43 0.5× 11 311
Zhaojun Lu China 12 49 0.3× 83 0.6× 29 0.3× 43 0.4× 71 0.8× 27 304
L. Robert Hanrahan United States 7 186 1.1× 35 0.3× 48 0.5× 51 0.5× 32 0.4× 10 334

Countries citing papers authored by Jan Štraub

Since Specialization
Citations

This map shows the geographic impact of Jan Štraub's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Štraub with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Štraub more than expected).

Fields of papers citing papers by Jan Štraub

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan Štraub. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Štraub. The network helps show where Jan Štraub may publish in the future.

Co-authorship network of co-authors of Jan Štraub

This figure shows the co-authorship network connecting the top 25 collaborators of Jan Štraub. A scholar is included among the top collaborators of Jan Štraub based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan Štraub. Jan Štraub is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Minařík, Jiří, Luděk Pour, Tomáš Jelı́nek, et al.. (2025). Lenalidomide based triplets in relapsed/refractory multiple myeloma: analysis of the Czech Myeloma Group. BMC Cancer. 25(1). 651–651.
2.
3.
Delimpasi, Sosana, Meletios Α. Dimopoulos, Jan Štraub, et al.. (2024). Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma. American Journal of Hematology. 99(9). 1746–1756. 3 indexed citations
4.
5.
Štork, Martin, Ivan Špıčka, Jakub Radocha, et al.. (2023). Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis. Annals of Hematology. 102(6). 1501–1511. 6 indexed citations
6.
Pour, Luděk, Ivan Špıčka, Jakub Radocha, et al.. (2023). P1294: REAL-WORLD OUTCOMES OF 2149 NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS. HemaSphere. 7(S3). e0151603–e0151603. 1 indexed citations
7.
Ocio, Enrique M., Yvonne A. Efebera, Roman Hájek, et al.. (2023). ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study. Haematologica. 109(3). 867–876. 5 indexed citations
8.
Štork, Martin, Sabina Ševčı́ková, Tomáš Jelı́nek, et al.. (2022). Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas. Biomedicines. 10(10). 2535–2535. 2 indexed citations
9.
Maisnar, Vladimír, Luděk Pour, Ivan Špıčka, et al.. (2022). Patient Characteristics, Treatment Patterns, and Outcomes in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Patients, a Retrospective Observational Study Using Czech Registry Data. Clinical Lymphoma Myeloma & Leukemia. 23(2). 145–153. 4 indexed citations
10.
Minařík, Jiří, Jakub Radocha, Alexandra Jungová, et al.. (2022). Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy. Cancers. 14(20). 5165–5165. 5 indexed citations
11.
Sandecká, Viera, Luděk Pour, Ivan Špıčka, et al.. (2022). Real-world evidence of efficacy and safety of pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: Czech registry data. Neoplasma. 69(6). 1474–1479. 2 indexed citations
12.
Štork, Martin, Sabina Ševčı́ková, Jiří Minařík, et al.. (2021). Identification of patients at high risk of secondary extramedullary multiple myeloma development. British Journal of Haematology. 196(4). 954–962. 11 indexed citations
13.
14.
15.
Minařík, Jiří, Tomáš Jelı́nek, Alexandra Jungová, et al.. (2018). Treatment of Relapsed and Refractory Multiple Myeloma with Fully Oral Triplet IRD (ixazomib, lenalidomide and dexamethasone) Is Safe and with Significant Therapeutic Outcomes. Blood. 132(Supplement 1). 1959–1959. 4 indexed citations
16.
17.
Paleček, Tomáš, et al.. (2012). Cardiac amyloidosis: A comprehensive review. Cor et Vasa. 55(1). e60–e75. 37 indexed citations
18.
Krejčí, Marta, Evžen Gregora, Jan Štraub, et al.. (2011). Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma. Annals of Hematology. 90(12). 1441–1447. 2 indexed citations
19.
Štraub, Jan, et al.. (2009). Mnohočetný myelom - časná diagnostika. 6(4). 197–199.
20.
Hallisey, Michael J., et al.. (1995). Angioplasty for the Treatment of Visceral Ischemia. Journal of Vascular and Interventional Radiology. 6(5). 785–791. 65 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Leanne McCulloch Breakdown of academic impact, for papers by Yeu‐Chin Chen Breakdown of academic impact, for papers by Yasufumi Matsuda Breakdown of academic impact, for papers by Ming‐Chih Chang Breakdown of academic impact, for papers by Álvaro Hernández Vicente Breakdown of academic impact, for papers by Ajoy Dias Breakdown of academic impact, for papers by M.C. Trzeciak Breakdown of academic impact, for papers by S. Luzi Fedeli Breakdown of academic impact, for papers by Zhaojun Lu Breakdown of academic impact, for papers by L. Robert Hanrahan
Rankless by CCL
2026